IRIS
ROTTOLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.246
EU - Europa 13.863
AS - Asia 6.239
SA - Sud America 1.159
AF - Africa 150
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 15
Totale 37.704
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.994
GB - Regno Unito 3.071
RU - Federazione Russa 2.614
CN - Cina 2.516
IT - Italia 1.998
IE - Irlanda 1.889
SG - Singapore 1.825
UA - Ucraina 1.067
BR - Brasile 991
SE - Svezia 948
DE - Germania 743
FR - Francia 690
HK - Hong Kong 553
FI - Finlandia 383
VN - Vietnam 352
KR - Corea 345
CA - Canada 159
IN - India 153
ES - Italia 101
TR - Turchia 98
JP - Giappone 69
BD - Bangladesh 67
PL - Polonia 63
AR - Argentina 60
NL - Olanda 55
MX - Messico 54
BE - Belgio 51
CZ - Repubblica Ceca 50
ZA - Sudafrica 48
IQ - Iraq 36
AT - Austria 29
AU - Australia 27
SA - Arabia Saudita 27
MA - Marocco 26
CI - Costa d'Avorio 25
EC - Ecuador 23
ID - Indonesia 22
UZ - Uzbekistan 22
CO - Colombia 21
PK - Pakistan 20
LT - Lituania 17
IL - Israele 16
VE - Venezuela 16
IR - Iran 14
AZ - Azerbaigian 12
JM - Giamaica 12
PT - Portogallo 12
PY - Paraguay 12
GR - Grecia 11
AE - Emirati Arabi Uniti 10
EU - Europa 10
KE - Kenya 10
PE - Perù 10
RO - Romania 10
UY - Uruguay 10
KG - Kirghizistan 9
TN - Tunisia 9
EG - Egitto 8
JO - Giordania 8
KZ - Kazakistan 8
BO - Bolivia 7
CH - Svizzera 7
CL - Cile 7
PH - Filippine 7
AL - Albania 6
BG - Bulgaria 6
DZ - Algeria 6
ET - Etiopia 6
LU - Lussemburgo 6
MY - Malesia 6
EE - Estonia 5
HU - Ungheria 5
BB - Barbados 4
CR - Costa Rica 4
CY - Cipro 4
DK - Danimarca 4
LV - Lettonia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
PA - Panama 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LK - Sri Lanka 3
NP - Nepal 3
OM - Oman 3
TJ - Tagikistan 3
TT - Trinidad e Tobago 3
AO - Angola 2
BN - Brunei Darussalam 2
GA - Gabon 2
GE - Georgia 2
LY - Libia 2
MD - Moldavia 2
Totale 37.671
Salva come PNG Salva come JPEG
Città #
Southend 2.703
Dublin 1.880
Dallas 1.831
Fairfield 1.793
Chandler 1.143
Ashburn 1.105
Singapore 1.068
Houston 894
Jacksonville 859
Woodbridge 781
Moscow 708
Beijing 700
Santa Clara 697
Seattle 650
Wilmington 599
Hong Kong 540
Cambridge 533
Ann Arbor 466
Siena 416
Princeton 361
Seoul 308
Hefei 273
Nanjing 272
Los Angeles 218
New York 218
Helsinki 164
Munich 158
The Dalles 158
Menlo Park 151
Boardman 146
Dearborn 119
Nanchang 117
Buffalo 111
San Diego 110
Florence 98
Dong Ket 95
Council Bluffs 92
Ho Chi Minh City 87
San Mateo 84
Milan 82
São Paulo 81
Shanghai 78
London 75
Shenyang 71
Málaga 67
Tokyo 62
Chicago 60
Tianjin 58
Rome 56
Hebei 54
Izmir 53
Düsseldorf 52
Changsha 51
Turku 50
Warsaw 50
Ottawa 48
Hanoi 47
Columbus 45
Kunming 45
Hangzhou 42
Montreal 41
Redondo Beach 40
Norwalk 39
Brussels 38
Guangzhou 38
Fremont 36
Jiaxing 36
Washington 36
Jinan 35
Johannesburg 35
San Francisco 34
San Jose 33
Brno 32
Catania 31
Rio de Janeiro 31
Bengaluru 30
Gavirate 30
Brooklyn 29
Denver 29
Toronto 29
Nuremberg 28
Poplar 28
Belo Horizonte 27
Chennai 27
Frankfurt am Main 27
Phoenix 26
Seongnam 26
Stockholm 26
Venezia 26
Zhengzhou 26
Boston 25
Redwood City 25
Abidjan 24
Amsterdam 24
Lancaster 21
Atlanta 20
Lastra a Signa 20
Ningbo 20
Gießen 19
Miami 18
Totale 25.098
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.025
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 429
Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients 429
null 398
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 356
Cytokine modulators in the treatment of sarcoidosis 350
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 320
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 307
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 287
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 270
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 259
Asbestos exposure assessment by mineralogical analysis of bronchoalveolar lavage fluid 256
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 253
Exhaled nitric oxide in interstitial lung diseases 252
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 252
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 250
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 248
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 247
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 244
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 243
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 242
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 241
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 237
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 237
A difficult case: sarcoidosis with CNS involvement or sarcoidosis associated with multiple sclerosis? 236
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 236
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 234
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 233
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 232
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 231
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 230
Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients 229
Bronchial stenosis following lung transplant: An innovative approach with a modified endobronchial emphysema valve 229
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 229
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 226
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 224
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 224
Serum amyloid A in patients with idiopathic pulmonary fibrosis 223
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 221
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 221
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 220
Diffuse panbronchiolitis in a patient with common variable immunodeficiency: a casual association or a pathogenetic correlation? 219
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 212
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 211
Chitotriosidase activity in patients with interstitial lung disesaes 209
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 209
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 206
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 205
2D electrophoretic maps of BAL proteins in fibrosing lung diseases 204
Adaptive immune responses in primary cutaneous sarcoidosis 203
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 203
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 203
Bone ultrasonography in glucocorticoid induced osteoporosis 203
Abnormalities in calcium metabolism in sarcoidosis 202
A functional proteomics approach to the comprehension of sarcoidosis 202
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 202
The analysis of tryptase in serum of sarcoidosis patients 201
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 201
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 199
Analysis of alveolar and peripheral CD45RO+ T-lymphocytes in sarcoidosis 198
Quality of life, anxiety and depression in Sarcoidosis 198
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease 198
The pharmacological treatment of bronchiectasis 197
Phenotypes of organ involvement in sarcoidosis 197
Proteome analysis of bronchoalveolar lavage in lung diseases 194
Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis 194
Assessment of cardiac involvement in sarcoidosis by echocardiography 194
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 193
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 192
Postoperative acute kidney injury in lung transplant recipients 192
A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis. 191
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 190
Serum analysis of coagulation factors in IPF and NSIP 190
Severe acute graft versus host disease after lung transplant: report of a case successfully treated with high dose corticosteroids 190
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension 190
Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia 190
Doubts and certainness in diagnosis of pulmonary embolism in the elderly 189
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 189
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial 189
Serum amyloid A: A potential biomarker of lung disorders 189
Extracorporeal Photopheresis in Lung Transplantation 188
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 187
Selection of Candidates for Lung Transplantation: The First Italian Consensus Statement 187
Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study 183
Biomarkers in sarcoidosis: The contribution of system biology 182
Sarcoidosis with upper respiratory tract involvement 181
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis 181
Gardening in greenhouses as a risk factor for silicosis. 180
Effects of calcitriol on IFN-gamma production by alveolar and peripheral lymphocytes of patients with sarcoidosis. 180
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 180
Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors 179
Proteomic investigation of pulmonary sarcoidosis 179
Pollen grain viability in Parietaria judaica L. during the long blooming period and correlation with meteorological conditions and allergic diseases 176
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 175
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 175
Concentrations of major elements and mercury in unstimulated human saliva 174
Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome 174
Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease 172
Urgent contralateral pneumonectomy after single lung transplantation for lymphangioleiomyomatosis. 172
IPF mortality in waiting list for lung transplantation 171
Totale 22.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.060
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.060
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.534 0 0 0 0 0 484 175 572 372 315 316 300
2021/20222.687 202 387 146 219 127 71 122 124 119 291 311 568
2022/20233.957 295 344 489 589 389 774 78 318 394 95 127 65
2023/20242.810 136 59 231 100 102 760 968 71 17 73 52 241
2024/20255.380 147 296 559 289 689 279 159 271 383 260 624 1.424
2025/20268.596 1.053 1.713 1.536 1.499 2.424 371 0 0 0 0 0 0
Totale 38.176